82
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

      editorial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

          Related collections

          Most cited references438

          • Record: found
          • Abstract: found
          • Article: not found

          Reporting results of cancer treatment.

          On the initiative of the World Health Organization, two meetings on the Standardization of Reporting Results of Cancer Treatment have been held with representatives and members of several organizations. Recommendations have been developed for standardized approaches to the recording of baseline data relating to the patient, the tumor, laboratory and radiologic data, the reporting of treatment, grading of acute and subacute toxicity, reporting of response, recurrence and disease-free interval, and reporting results of therapy. These recommendations, already endorsed by a number of organizations, are proposed for international acceptance and use to make it possible for investigators to compare validly their results with those of others.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

              Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, we describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in December 2005 - was completed in just 11 years, with approval being received approximately 5 years after the initiation of the first Phase I trial.
                Bookmark

                Author and article information

                Contributors
                aug8808@yahoo.co.jp
                Journal
                Hepatol Int
                Hepatol Int
                Hepatology International
                Springer India (New Delhi )
                1936-0533
                1936-0541
                15 June 2017
                15 June 2017
                July 2017
                : 11
                : 4
                : 317-370
                Affiliations
                [1 ]ISNI 0000 0004 0377 4044, GRID grid.417333.1, Department of Gastroenterology, , Yamanashi Prefectural Central Hospital, ; Kofu-city, Yamanashi Japan
                [2 ]ISNI 0000 0001 2151 536X, GRID grid.26999.3d, , The University of Tokyo, ; Tokyo, Japan
                [3 ]ISNI 0000 0004 0546 0241, GRID grid.19188.39, Department of Oncology and Internal Medicine, National Taiwan University Hospital, National Taiwan University Cancer Center and Graduate Institute of Oncology, , National Taiwan University, ; Taipei, Taiwan
                [4 ]ISNI 0000 0001 2151 536X, GRID grid.26999.3d, Hepato-Biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, , The University of Tokyo, ; Tokyo, Japan
                [5 ]ISNI 0000 0004 1936 9967, GRID grid.258622.9, Department of Gastroenterology and Hepatology, , Kindai University School of Medicine, ; Osaka-Sayama, Osaka Japan
                [6 ]ISNI 0000 0004 0470 5905, GRID grid.31501.36, Department of Radiology and Institute of Radiation Medicine, , Seoul National University College of Medicine, ; Seoul, Republic of Korea
                [7 ]ISNI 0000 0004 0369 153X, GRID grid.24696.3f, Beijing Key Laboratory of Translational Medicine on Cirrhosis, National Clinical Research Center for Digestive Diseases, Liver Research Center, Beijing Friendship Hospital, , Capital Medical University, ; Beijing, China
                [8 ]ISNI 0000 0001 2151 536X, GRID grid.26999.3d, Department of Gastroenterology, Graduate School of Medicine, , The University of Tokyo, ; Tokyo, Japan
                [9 ]ISNI 0000 0004 0470 5454, GRID grid.15444.30, Department of Internal Medicine, , Yonsei University College of Medicine, ; Seoul, Republic of Korea
                [10 ]ISNI 0000 0004 1767 2903, GRID grid.415131.3, Department of Hepatology, , Postgraduate Institute of Medical Education and Research, ; Chandigarh, India
                [11 ]ISNI 0000 0004 1762 2738, GRID grid.258269.2, Department of Gastroenterology, , Juntendo University, ; Tokyo, Japan
                [12 ]ISNI 0000 0004 0606 972X, GRID grid.411190.c, Department of Medicine, , Aga Khan University and Hospital, ; Karachi, Pakistan
                [13 ]Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines
                [14 ]ISNI 0000 0004 1764 753X, GRID grid.415980.1, Department of Gastroenterology, , Mitsui Memorial Hospital, ; Tokyo, Japan
                [15 ]ISNI 0000 0004 0370 1101, GRID grid.136304.3, Department of Gastroenterology and Nephrology, Graduate School of Medicine, , Chiba University, ; Chiba, Japan
                [16 ]ISNI 0000 0004 0572 7815, GRID grid.412094.a, Department of Internal Medicine, , National Taiwan University Hospital, ; Taipei, Taiwan
                [17 ]ISNI 0000000120191471, GRID grid.9581.5, Digestive Disease and GI Oncology Center, Medistra Hospital, , University of Indonesia, ; Jakarta, Indonesia
                [18 ]ISNI 0000000120191471, GRID grid.9581.5, Department of Internal Medicine, Cipto Mangunkusumo Hospital, , University of Indonesia, ; Jakarta, Indonesia
                [19 ]ISNI 0000 0000 9239 9995, GRID grid.264706.1, Third Department of Internal Medicine, , Teikyo University School of Medicine, ; Chiba, Japan
                [20 ]ISNI 0000000109409118, GRID grid.7256.6, Department of Gastroenterology, , Ankara University School of Medicine, ; Ankara, Turkey
                [21 ]ISNI 0000 0004 1804 4108, GRID grid.418784.6, Department of Hepatology, , Institute of Liver and Biliary Sciences, ; New Delhi, India
                Article
                9799
                10.1007/s12072-017-9799-9
                5491694
                28620797
                993f4f27-2272-47e3-acd3-2be5a91e0a04
                © The Author(s) 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 6 January 2017
                : 2 May 2017
                Categories
                Guidelines
                Custom metadata
                © Asian Pacific Association for the Study of the Liver 2017

                Gastroenterology & Hepatology
                hepatocellular carcinoma,asia–pacific,apasl,treatment algorithm

                Comments

                Comment on this article